Source:http://linkedlifedata.com/resource/pubmed/id/10430979
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1999-8-23
|
| pubmed:abstractText |
In 1994, we reported a 3.4 +/- 0.8 year follow-up of the eight patients who experienced remission of nephrotic syndrome during the Collaborative Study Group-sponsored, multicenter trial of captopril therapy in patients with type 1 diabetes with nephropathy (Captopril Study). Of the 409 patients randomized to treatment on the Captopril Study, 108 had nephrotic syndrome (24-hour proteinuria >/= 3.5 g of protein) at baseline. Of these 108 patients, 8 experienced remission of nephrotic syndrome (proteinuria </= 1.0 g/24 h of protein). Remission was significantly associated with captopril therapy and control of systolic blood pressure. The present study describes the status of these eight patients during a follow-up of 7.7 +/- 0.3 years. Since our previous report, one patient has been lost to follow-up and one patient progressed to end-stage renal disease (ESRD) 3.7 years after completion of the Captopril Study. The remaining six patients remain in remission of nephrotic syndrome (mean 24-hour proteinuria, 1.03 +/- 0.3 g of protein) and have stable serum creatinine levels (mean, 1.58 +/- 0.3 mg/dL) and body weights (mean, 69.8 +/- 5.3 kg). Of the six patients, one has discontinued angiotensin-converting enzyme inhibitor (ACEi) therapy because of hypotension. Excluding the patient who progressed to ESRD, the current mean systolic blood pressure is 135 +/- 6 mm Hg and mean diastolic blood pressure is 78 +/- 4 mm Hg. We conclude that long-term remission of nephrotic syndrome and preservation of renal function is achievable in some patients with type 1 diabetes. Control of blood pressure and ACEi therapy appear to be important in achieving long-term remission.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1523-6838
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
34
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
308-14
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10430979-Adult,
pubmed-meshheading:10430979-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:10430979-Antihypertensive Agents,
pubmed-meshheading:10430979-Blood Pressure,
pubmed-meshheading:10430979-Captopril,
pubmed-meshheading:10430979-Creatinine,
pubmed-meshheading:10430979-Diabetes Mellitus, Type 1,
pubmed-meshheading:10430979-Diabetic Nephropathies,
pubmed-meshheading:10430979-Disease Progression,
pubmed-meshheading:10430979-Female,
pubmed-meshheading:10430979-Follow-Up Studies,
pubmed-meshheading:10430979-Humans,
pubmed-meshheading:10430979-Kidney Failure, Chronic,
pubmed-meshheading:10430979-Male,
pubmed-meshheading:10430979-Middle Aged,
pubmed-meshheading:10430979-Nephrotic Syndrome,
pubmed-meshheading:10430979-Prospective Studies,
pubmed-meshheading:10430979-Proteinuria,
pubmed-meshheading:10430979-Randomized Controlled Trials as Topic,
pubmed-meshheading:10430979-Remission Induction
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study.
|
| pubmed:affiliation |
Northeast Ohio University College of Medicine, Columbus, OH, USA.
|
| pubmed:publicationType |
Journal Article
|